Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia or as adjunctive treatment for major depressive disorder. As obesity (body mass index ≥35 kg/m2) has the potential to affect drug pharmacokinetics and is a common comorbidity of both schizophrenia and major depressive disorder, it is important to understand changes in brexpiprazole disposition in this population. This study uses a whole-body physiologically-based pharmacokinetic (PBPK) model to compare the pharmacokinetics of brexpiprazole in obese and normal-weight (body mass index 18- 25 kg/m2) individuals known to be cytochrome P450 2D6 extensive metabolizers (EMs) and poor metabolizers (PMs).
- Provider:American College of Clinical Pharmacology
- Activity Link: https://www.accp1.org/Members/Continuing_Education/Virtual_Journal_Club/ACCP1/4Continuing_Education/Virtual_Journal_Club.aspx?hkey=58999de8-6827-42f2-95a0-953fc6102c3a
- Start Date: 2022-03-16 05:00:00
- End Date: 2022-03-16 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest